CELL INTELLIGENCE · 肿瘤细胞治疗研究

从 CAR-T 到 CAAR-T：通过独特型导向细胞治疗重新定义 B 细胞恶性肿瘤的靶向策略

From CAR-T to CAAR-T: redefining targeting strategies in B-cell malignancies through idiotype-directed cellular therapy.

整合跨膜 CD28 结构域后学术性 CAR-T ARI0002h 对正常和低表达 BCMA 骨髓瘤细胞增强的抗肿瘤活性

Enhanced antitumoral activity of the academic CAR-T ARI0002h against normal and low BCMA-expressing myeloma cells after incorporating a transmembrane

将 CD28-TMD 整合到 ARI0002h CAR 中可增强肿瘤控制，即使在靶抗原下调的复发模型中也是如此，从而提供更好的长期疾病管理。该修饰增强了对 BCMA 表达正常和降低的 MM 肿瘤细胞系的效力，表现出更优的代谢耐力和体内活性。

抗 CD19/22 与抗 BCMA 双靶向 CAR-T 细胞疗法用于一例多发性骨髓瘤合并继发性 B-ALL 患者

Dual anti-CD19/22 and anti-BCMA CAR T-cell therapy in a patient with multiple myeloma and secondary B-ALL.

CRISPR/Cas9 TCR 编辑的 NKp30 CAR-T 细胞对表达 B7H6 的白血病与黑色素瘤表现出更强的抗肿瘤免疫

CRISPR/Cas9 TCR-Edited NKp30 CAR T Cells Exhibit Superior Anti-Tumor Immunity to B7H6-Expressing Leukemia and Melanoma.

接受 CAR-T 细胞治疗的血液恶性肿瘤患者的健康相关生活质量：综述与当前进展

Health-related quality of life in patients with hematologic malignancies treated with chimeric antigen receptor T-cell therapy: review and current pro

CAR 与嵌合共刺激受体联用增强 T 细胞对低抗原密度的敏感性并促进持久性

Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.